Paul Perreault, CSL Behring's chief executive (file photo)

In an un­ex­pect­ed twist, CSL buys world­wide rights to uniQure's PhI­II he­mo­phil­ia B gene ther­a­py in $2B-plus deal

In a sur­prise move, CSL Behring re­port­ed af­ter the mar­ket closed on Wednes­day that it is ac­quir­ing uniQure’s Phase III he­mo­phil­ia B gene ther­a­py with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.